Summit Therapeutics (SMMT) Profit After Tax (2019 - 2026)

Summit Therapeutics has reported Profit After Tax for 8 years, with the latest figure at -$189.4 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 201.09% year-over-year to -$189.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 billion (down 400.96% YoY), and the FY2025 full-year result was -$1.1 billion, down 387.81% from the prior year.
• Profit After Tax for Q1 2026 stood at -$189.4 million, up from -$219.2 million in the prior quarter.
• The five-year high for Profit After Tax was -$14.7 million in Q2 2023, with the low at -$565.7 million in Q2 2025.
• Historically, Profit After Tax has averaged -$128.5 million across 5 years, with a median of -$56.3 million in 2024.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 2434.82% — and 2024, when it soared 91.98%.
• Summit Therapeutics' Profit After Tax stood at -$19.2 million in 2022, then sank by 90.17% to -$36.6 million in 2023, then tumbled by 67.37% to -$61.2 million in 2024, then tumbled by 258.11% to -$219.2 million in 2025, then increased by 13.57% to -$189.4 million in 2026.
• The last three Profit After Tax figures came in at -$189.4 million (Q1 2026), -$219.2 million (Q4 2025), and -$231.8 million (Q3 2025), per Business Quant data.